Streamline for QRxPharma
Tuesday, 05 August, 2008
The US Food and Drug Administration has granted approval to QRxPharma's [ASX: QRX] streamlined Phase III development plan for lead candidate Q8003IR.
This approval means that QRxPharma will be required to conduct only two Phase III trials for New Drug Agreement [NDA] filing. No additional pharmacology, toxicology or long term clinical safety studies will be required.
Q8003IR is an immediate release dual-opioid containing both morphine and oxycodone, and is intended to be used in the management of moderate to severe pain.
The FDA did make some changes to QRxPharma's proposal, but according to company representatives these changes were minimal.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
